Performance of a DNA methylation marker panel in cervical samples from women with abnormal cytology findings
Year: 2026
Type: article
Study design: Observational Study
Abstract: Reliable triage methods are essential in cervical cancer screening to avoid overtreatment. DNA methylation markers offer an objective molecular readout with potential to keep false-positive rates low. We evaluated the GynTect ® DNA methylation assay as a triage marker in cervical samples from women with abnormal cytology, in comparison with the p16/Ki-67 Dual Stain test CINtec Plus ® . Surplus liquid-based cytology samples from 1,000 women with cytology ≥ PAP III (Low-Grade Squamous Intraepithelial Lesion = LSIL, or worse) were tested with GynTect ® (markers: ASTN1, DLX1, ITGA4, RXFP3, SOX17, ZNF671). cobas ® HPV and p16/Ki-67 Dual Stain (CINtec Plus ® ) results were available for all samples; histopathology was available for a subset of 601 samples. Positivity rates with 95% confidence intervals were calculated using the Wilson score method. Overall GynTect positivity was 27.7% versus 88.3% for p16/Ki-67 Dual Stain. Methylation positivity correlated with cytological severity: 17.0% in LSIL, 30.2% in moderate High-Grade Squamous Intraepithelial Lesion HSIL, and 65.0% in the PAP IV group (high-grade SIL/AIS and HSIL suspicious for invasion). Among HPV16/18-positive samples, 38.4% were GynTect-positive versus 94.8% p16/Ki-67 Dual Stain-positive. By histopathology, GynTect positivity was 15.0% (CIN I), 27.0% (CIN II), and 56.5% (CIN III); all four cancer cases were GynTect- and p16/Ki-67 Dual Stain-positive. Of 191 GynTect-positive cases with histopathology, 73% had CIN II or CIN III. GynTect positivity (27.7%) was significantly lower than p16/Ki-67 Dual Stain positivity (88.3%), with a statistically significant monotonic trend across increasing cytological severity (Cochran-Armitage trend test, p < 0.001) and histopathological categories ( p < 0.001). All four histologically confirmed carcinomas were GynTect-positive. These findings are consistent with a potential role for GynTect in selective triage after abnormal cytology, with lower positivity rates suggesting higher selectivity for high-grade disease compared with p16/Ki-67 Dual Stain. Prospective validation in primary HPV-screening triage populations is required to determine whether this translates into clinical benefit.
Source: BMC Women s Health
Authors: Ilona Zeiser(Conceptualization, Data curation, Formal analysis, Writing – review & editing), Katja Schubert(Methodology, Writing – review & editing), Juliane Hippe(Methodology, Writing – review & editing), Alfred Hansel(Methodology, Writing – original draft, Writing – review & editing), Martina Schmitz(Methodology, Writing – review & editing), Magnus von Knebel Doeberitz(Writing – review & editing), Andrè Ahr(Conceptualization, Formal analysis, Supervision, Writing – review & editing), Hans Ikenberg(Conceptualization, Data curation, Formal analysis, Supervision, Writing – review & editing)
Institutions: oncgnostics (Germany), University Hospital Heidelberg
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,890
OpenAlex ID: W7236172397
